Upcoming Financial Release by Celcuity Inc.
Celcuity Inc. (Nasdaq: CELC), a promising clinical-stage biotechnology company, is eagerly preparing to unveil its financial results for the second quarter of 2025. The company has announced that this release will take place following the market's closing on a Thursday, with updates scheduled shortly thereafter. Management will engage with stakeholders via a live webcast and teleconference at 4:30 p.m. Eastern Time on the same day.
Webcast and Conference Participation Details
For those who wish to listen in on this insightful session, domestic participants can connect by calling 1-800-717-1738, while international callers are encouraged to dial 1-646-307-1865. The company will also stream the event live, allowing easy access for everyone interested in tracking Celcuity's latest developments and financial standing. A recording of this event will be made available on the company's website shortly after.
About Celcuity Inc.
Celcuity is dedicated to developing innovative targeted therapies aimed at treating a variety of solid tumors. Central to its mission is gedatolisib, a groundbreaking, potent pan-PI3K and mTORC1/2 inhibitor that effectively disrupts the PAM pathway. Its unique mechanism of action differentiates it significantly from other treatments that target PI3K?, AKT, or mTORC1 either in isolation or combination. This innovative approach could markedly improve patient outcomes in oncology.
Ongoing Clinical Trials
The company is currently conducting critical Phase 3 and Phase 1/2 clinical trials to evaluate gedatolisib's efficacy in various treatment settings. One notable trial, VIKTORIA-1, assesses gedatolisib in combination with fulvestrant, with or without palbociclib, for patients suffering from HR+/HER2- advanced breast cancer. This pivotal study is currently enrolling participants, indicating the strong commitment of Celcuity to advancing cancer treatments.
Another significant study, CELC-G-201, explores the combination of gedatolisib and darolutamide in patients diagnosed with metastatic castration-resistant prostate cancer. Similarly, VIKTORIA-2 is a reputable Phase 3 trial looking at gedatolisib combined with a CDK4/6 inhibitor alongside fulvestrant as a first-line treatment for HR+/HER2- late-stage breast cancer. Both studies demonstrate Celcuity's strategic focus on targeted therapy development for difficult-to-treat conditions.
More Information About Celcuity
Celcuity is headquartered in Minneapolis, where it continues to foster innovation in its clinical pursuits. For anyone interested in learning more about their active trials and corporate initiatives, detailed information can be accessed through the company's official website, where additional resources and updates can be found.
Company Contacts
For further inquiries, stakeholders may contact Brian Sullivan at bsullivan@celcuity.com or Vicky Hahne at vhahne@celcuity.com. They can also be reached through the phone number (763) 392-0123.
Additionally, those wishing to communicate through ICR Healthcare can reach out to Patti Bank at patti.bank@icrhealthcare.com, or by calling (415) 513-1284.
Frequently Asked Questions
What is the purpose of Celcuity’s upcoming conference call?
The call is designed to discuss the company’s financial results for Q2 2025 and to provide updates on its clinical programs.
How can I participate in the conference call?
Participants can join by dialing the specified domestic and international phone numbers, or by accessing the live webcast available on the company's website.
What is gedatolisib and why is it significant?
Gedatolisib is Celcuity's lead therapeutic candidate, noted for its unique approach in inhibiting the PAM pathway, which may improve treatment responses compared to existing therapies.
What clinical trials is Celcuity currently conducting?
Celcuity is conducting several pivotal studies, including VIKTORIA-1 and CELC-G-201, focusing on breast cancer and prostate cancer therapies, respectively.
Where can I find more information about Celcuity?
Detailed information and updates regarding Celcuity and its clinical trials are available on the company’s official website.
